CNS company Minerva sets IPO range

Minerva Neurosciences Inc. (Cambridge, Mass.) amended its planned IPO on NASDAQ and plans to sell 5.5 million shares at $10-$12. At the $11 midpoint, the company would raise $60 million and be valued at $185.8 million. Jefferies; Baird; and JMP Securities are underwriters. In 4Q14, Minerva plans to start a Phase IIb trial of MIN-101 to treat schizophrenia. Also next half, the company plans to start a Phase II trial of MIN-117 to treat major depressive disorder (MDD). ...